The availability of specific inhibitors targeting mutated BRAF and the downstream MAPK signalling pathway or other kinases activated in melanoma, together with immunotherapies that de-block inhibition of T cell responses against the tumour, offer potent ways to fight this cancer [23]. This evidence concerns the gene BRAF and melanoma.